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Abstract
Background: In Portugal, colorectal cancer is the second 
most common type of cancer. With the increasing number 
of cancer survivors, follow-up is perceived as a chronic dis-
ease, with a significant impact on hospital care. Objective: 
To characterize colorectal patients in follow-up at Centro 
Hospitalar Lisboa Norte, EPE, and to determine the profile of 
economic resources consumed as well as the consultation 
workload. Materials and Methods: We characterized 
colorectal patients in follow-up at Centro Hospitalar Lisboa 
Norte, EPE, registered from 2008 until 2013 and the profile of 
economic resources consumed. Results: The Department of 
Oncology is responsible for 56.2% of colorectal patients’ fol-
low-up. In this study, only 0.4% of cases had follow-up se-
cured in primary care, which translates to a significant im-
pact in terms of resources allocation and consultation man-
agement, especially if we consider that 41% of patients are 
in follow-up for longer than 3 years. The average annual ad-
justed cost of follow-up per patient is EUR 539.09. Patients 
who were alive on 31 January 2014 had generated 2,930 fol-
low-up hospital appointments per year, representing 12% of 
the total number of oncology appointments reported in 
2013. Discussion and Conclusions: The follow-up of colorec-
tal cancer patients is associated with significant hospital re-
source allocation and physicians’ time consumption. Other 
follow-up models might emerge as an alternative to tradi-
tional hospital-centered follow-up, such as the shared-care 
follow-up, which requires a multidisciplinary and survivor-
centered approach, ensuring that information and commu-
nication are shared between settings with a clear definition 
of responsibilities, a survivor care plan, and mechanisms for 
future referencing when justified.
© 2018 The Author(s). Published by S. Karger AG, Basel 
on behalf of NOVA National School of Public Health
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Podem os Cuidados de Saúde Primários 
desempenhar um papel no follow-up de doentes 
com cancro colorretal? O caso de um Hospital 
Universitário português
Palavras Chave
Integração de cuidados · Gestão da doença · Cancro 
colorretal · Seguimento · Sobrevivente
Resumo
Introdução: Em Portugal o cancro colorretal é o segundo 
cancro mais frequente. Com o aumento do número de 
sobreviventes de cancro, o seguimento acaba por ser en-
carado como uma condição crónica, com impacto signifi-
cativo nos cuidados assistenciais hospitalares. Objetivo: 
Caraterizar os doentes com cancro colorretal em segui-
mento no Centro Hospitalar Lisboa Norte, EPE. e determi-
nar o perfil de recursos económicos consumidos, bem 
como a carga assistencial. Material e Métodos: Procedeu-
se à caraterização dos doentes com cancro colorretal em 
seguimento no Centro Hospitalar Lisboa Norte, EPE. regis-
tados de 2008 a 2013 e à determinação do perfil de recur-
sos económicos consumidos. Resultados: A oncologia é 
responsável pelo seguimento em 56,2% dos doentes com 
cancro colorretal. Neste estudo, apenas 0,4% dos casos 
tiveram um seguimento nos Cuidados de Saúde Primári-
os, o que se traduz num impacto significativo em termos 
dos recursos alocados e gestão de consultas, em especial 
se considerarmos que 41% dos doentes estão em segui-
mento há mais de 3 anos. O custo anual ajustado por 
doente é em média 539,09 €. Os doentes vivos a 31 janei-
ro de 2014 geraram 2930 consultas de seguimento por 
ano, equivalentes a 12% do total de consultas reportadas 
em 2013 pela oncologia. Discussão e Conclusão: O segui-
mento dos doentes com cancro colorretal está associado 
a uma alocação significativa de recursos hospitalares e 
consumo de tempo dos médicos. Outros modelos de se-
guimento, tais como o seguimento partilhado, poderão 
emergir como uma alternativa ao seguimento tradicional 
centrado no hospital, os quais requerem uma abordagem 
multidisciplinar e centrada no sobrevivente de cancro, as-
segurando que a informação e comunicação são partilha-
das entre níveis de prestação de cuidados, com uma 
definição clara de responsabilidades, um plano de cuida-
dos para o sobrevivente e mecanismos de referenciação 
futura se necessária.
© 2018 The Author(s). Published by S. Karger AG, Basel 
on behalf of NOVA National School of Public Health
Introduction
The incidence of colorectal cancer in Portugal is 7,127 
new cases/year, and the 5-year prevalence is 19,613 cases, 
which makes it the second most common type of cancer 
[1]. In 2013, colorectal cancer was responsible for the sec-
ond highest number of life years lost due to cancer [2]. 
The treatment and prognosis depend on disease staging, 
and stages I, II, and III are treated with surgical resection.
In Western countries, colorectal cancer survivors rep-
resent the third largest group of cancer survivors (∼11% 
of the population) [3], and the costs associated with on-
cologic care are growing and might be associated with a 
lack of coordination and organization in care, duplicated 
services and health-care fragmentation [4, 5].
Some reviews of the literature including studies from 
different countries (USA, Canada, Australia, UK, The 
Netherlands, Denmark, Sweden, Norway, Finland, Ger-
many, Italy, Japan) suggest that follow-up, a standard 
practice after surgical resection or treatment, when per-
formed by family physician is as effective as the follow-up 
held in the hospital setting and generates a higher degree 
of satisfaction and subjective health reported by the pa-
tient [4, 6].
Colorectal cancer follow-up performed by general 
practitioners versus surgeons was not associated with a 
significant difference between groups at 2-year follow-up 
in patient satisfaction, showing a difference only in the 
type and number of tests requested, with similar results 
for death or recurrence rate (p = 0.67) (p = 0.92), time to 
detection of recurrence (p = 0.76), and time to death (p = 
0.69)[7]. A French study found that patients under rou-
tine clinical examinations performed by general practi-
tioners had significantly less advanced disease (odds ra-
tio: 0, 45; 95% CI), fewer preoperative complications 
(odds ratio: 0, 28; 95% CI) and fewer examinations by 
gastroenterologists/oncologists (odds ratio: 0, 37; 95% 
CI), without any influence on 3- and 5-year survival [8].
Another study concluded that a decentralized colon 
cancer follow-up program does not impair quality of life, 
and is associated with an improvement in subscales such 
as role functioning, emotional functioning and pain, and 
cost savings due to decreased costs of primary care con-
sultations and fewer trips to hospital, without an increase 
in time to diagnosis of a serious clinical event or a differ-
ence in frequency of a serious clinical event [9].
Additionally, the use of extensive information from 
specialist clinics has been assessed in several studies, and 
the absence of primary care physicians in hospital multi-
disciplinary teams identified as a weakness, while the in-
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formation shared by hospital specialists with patients is 
insufficient [10–12].
A Canadian study concluded that 49.1% of general 
practitioners are responsible for the exclusive follow-up 
of colorectal cancer patients 5 years after diagnosis, and 
22.3% are willing to assume exclusive responsibility for 
follow-up immediately after completion of active treat-
ment, while 37.7% are willing to assume such responsibil-
ity 1–3 years after completion of active treatment [13]. 
General practitioners believe that specialist follow-up is 
important mainly because it ensures that, in case of recur-
rence, patients are in the system (67.2%); however, they 
also believe that specialist clinics are overcrowded 
(55.6%), better placed to provide psychosocial support to 
patients (79.8%) and should be involved at an early stage 
of follow-up (63.7%) [13].
Most oncologists agree that the greatest advantage of 
primary care setting involvement is that it allows them to 
concentrate on the acute phase of oncologic disease [14] 
and that follow-up is a distinct type of consultation due 
to its low efficiency and simplicity, the supportive and 
educational role of the physician being crucial but also 
associated with a considerable workload [15].
Although comorbid conditions might represent a ma-
jor threat to cancer survivors’ lives, they can be put in the 
background due to the centralization of hospital follow-
up and focus on cancer [16, 17]. An analysis of 18,699 
colorectal cancer survivors revealed that they may have a 
lower probability of receiving the recommended care for 
chronic medical conditions or preventive care not related 
to oncologic disease, which seems to improve when pri-
mary care physicians are involved in follow-up [17–19]. 
Follow-up by primary care practitioners is not associ-
ated with significant differences in quality of life, anxiety, 
depression, or patient satisfaction; in fact, a shared care 
model is associated with amelioration of patient satisfac-
tion, trust in caregivers, and intersectorial cooperation 
[20–21]. The use of information integrated systems seems 
to facilitate the implementation of such a model [22].
Nevertheless, despite the evidence in favor of alterna-
tive models to hospital follow-up, some patients continue 
to be discharged without the proper information and op-
portunity to choose their follow-up model [23]. About 
one-third of patients 5–16 years after diagnosis continue 
without hospital discharge, and some mention insuffi-
cient time, information, or adverse emotions when they 
are discharged [24]. Although the expectations of pa-
tients, oncologists, and general practitioners are different, 
with oncologists expecting from general practitioners a 
bigger intervention in the follow-up, patients and prima-
ry care physicians believe that there is also an important 
role in diagnosis and treatment phases [25], with a clear 
need to redefine the role of the primary care setting and 
ensure better communication and integrated manage-
ment of oncologic disease.
Objectives
The objectives of this work were (a) to characterize 
colorectal patients in follow-up at Centro Hospitalar Lis-
boa Norte, EPE, and (b) to determine the profile of eco-




A B-On (Online Knowledge Library) comprehensive literature 
search was conducted using the key words “integration of care in 
oncology,” “integrated disease management in cancer,” “cancer 
patients follow-up,” “colorectal cancer follow-up,” “cancer survi-
vorship,” and “colorectal cancer primary care follow-up.” In total, 
110 papers with available full texts and directly related to the scope 
of the topic were selected.
Study Design
For the clinical and sociodemographic characterization of co-
lorectal cancer patients in follow-up at the University Hospital 
Centro Hospitalar Lisboa Norte, EPE (CHLN, EPE), we developed 
an observational and cross-sectional study, based on available in-
formation obtained from the tumor bank database regarding 
colorectal cancer patients registered from 2008 to 2013, including 
only patients diagnosed up to 31 December 2013. The information 
was anonymized, and the study approved by the Hospital Ethics 
Committee.
The determination of the profile of resource consumption by 
colorectal patients in follow-up at this institution was based on the 
analysis of anonymized data for a sample of stage II colorectal can-
cer patients available at the Clinic Electronic Record. The informa-
tion was collected by two health-care professionals from the Lis-
bon Medicine Academic Center based on two registry spread-
sheets previously approved by the Hospital Ethics Committee.
The economic-financial impact on the institution was calcu-
lated using as a reference the prices of Portaria No. 20/2014, which 
defines the prices associated with National Health Care services. 
For each category, we grouped laboratory and imaging tests (Table 
1). The human resource workload was assessed using as a reference 
the number of follow-up consultations registered at that institu-
tion.
Additionally, a comparative analysis was conducted of the av-
erage per patient resource consumption according to the study 
results and when applying ESMO Guidelines at the follow-up of 
colorectal cancer patients [3].
Study Population and Exclusion Criteria
Patients with histologically confirmed colorectal cancer, aged 
at least 18 years, living in continental Portugal, in follow-up from 
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2008 to 2013 at CHLN, EPE, and registered at the tumor bank da-
tabase of the Medicine Academic Centre were included in the 
study. From an initial sample of 520 patients, we excluded all the 
cases without a confirmed histology of the primary tumor as ade-
nocarcinoma of the colon, adenocarcinoma of the rectum or 
colorectal carcinoma metastasis, which ended in a final sample of 
511 patients.
For the determination of the resource consumption profile, we 
selected 30 cases of patients with colorectal cancer stage II strati-
fied into 20 cases without recurrence (67%) and 10 cases with re-
currence (33%). Cases without the required information available 
or with incomplete information were excluded. To compare the 
average consumption of resources per patient follow-up based on 
the study and using ESMO Guidelines, we selected a sample of 14 
cases of patients with colon cancer without recurrence in which the 
most intensive follow-up approach had been adopted. Chest and 
abdominal computed tomography are only recommended in pa-
tients at high risk of recurrence. Due to the absence of such infor-
mation in patients’ records, we adopted an intermediate scenario 
in which all patients in the study sample would be considered eli-
gible on an annual basis for those exams. 
Statistical Methods
For the characterization of colorectal cancer patients in follow-
up, descriptive statistics were computed based on frequency tables 
for categorical variables and mean, median, mode, and standard 
deviation for numerical variables. The follow-up period was com-
puted considering the range between the date of surgery and the 
last date of the database update (January 31, 2014). The character-
ization of resource consumption (MCDT tests, costs of follow-up) 
was also based on descriptive statistics, stratified by gender and 
type of tumor.
To compare the distributions of follow-up costs with recur-
rence occurrence, we used the Mann-Whitney test. Considering 
the recurrence occurrence as the event under study, the association 
with follow-up costs was analyzed through the area under the ROC 
curve. The correlation between the adjusted annual cost of follow-
up and the duration of follow-up was performed by linear regres-
sion. All the tests were bilateral and with a significance level of 5%. 
All data were analyzed using IBM SPSS® Statistics (version 21). 
The resource consumption profile of patients in follow-up was de-
termined using Microsoft Excel 2010.
Results
Characterization of Patients in Follow-Up at CHLN
The average age of patients included in the study was 
69.0 years, the median was 70 years, and the majority were 
male (57.7%). A very high proportion of primary tumors 
were adenocarcinomas of the colon (72.4%) followed by 
adenocarcinomas of the rectum (26.2%). At diagnosis, 
most patients had disease stage II (36.4%) or III (32.1%). 
Only 13 patients (5%) experienced a recurrence during 
the period of analysis, and 29 patients (9%) developed 
distant metastases. Around 79% of patients had multiple 
metastases in two or more organs. Liver involvement was 
present in 71% of patients; in 52%, it was the only site, 
while 35% and 8% of patients had lung and peritoneal in-
volvement, respectively.
Table 1. NHS costs of tests/procedures (Portaria No. 20/2014)
Tests Category DRG Cost, EUR
Physical examination = Clinical visit Article 15° 31.00
Complete blood count Laboratory tests 24209 4.70
Liver function tests: Alk Fos, SGOT, SGPT, LDH, total 
bilirubin, GGT
Laboratory tests 25013, 24347, 21935, 21217, 
21220, 21665, 21344, 21340
8.10
Carcinoembryonic antigen test (CEA) Laboratory tests 21258 7.20
Total colonoscopy Endoscopy 50940 73.80
Colonoscopy with biopsy or polypectomy Endoscopy 50940, 31016 122.20
Flexible sigmoidoscopy Endoscopy 52270 55.20
Chest radiography (two incidences) Imaging 10406 9.00
Barium enema radiography Imaging 11200 23.00
Ultrasonography (echography of the abdomen superior) Imaging 17130 20.12
CT of the thorax, abdomen, pelvis Imaging 16060, 16070, 16080 220.79
CT of the abdomen, pelvis Imaging 16070, 16080 146.09
CT of the thorax Imaging 16060 74.70
CT of the thorax, abdomen Imaging 16060, 16070 159.20
CT cranioencephalic Imaging 16010 67.00
CT of the column Imaging 16041, 16042, 16043, 16044 72.40
Magnetic resonance imaging of the abdomen Imaging 18070 127.90
Magnetic resonance imaging of the abdomen, pelvis Imaging 18070, 18080 255.80
Magnetic resonance imaging of the column Imaging 18042 127.90
Magnetic resonance imaging cranioencephalic Imaging 18010 127.90
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The status alive/dead was known in 485 of 511 patients 
included in the analysis, 77.1% of whom were alive during 
the analysis period. Around 9% of patients were treated 
with neoadjuvant radiotherapy (47/508), 9% with neoad-
juvant chemotherapy (48/507), 4.7% with adjuvant radio-
therapy (24/473), and 52.6% with adjuvant chemotherapy 
(269/468), which, in some cases, was a combination of 
both chemo- and radiotherapy.
The specialty responsible for follow-up was oncology 
in more than half of the cases (56.2%), surgery in 21%, 
both in 0.4%, and primary care in 0.4%. The average fol-
low-up time was 31.9 months, with a maximum of 80 
months. Of all patients, 40.9% were in follow-up for more 
than 3 years, 8.8% of those (n = 44) for more than 5 years. 
We did not find any statistically significant difference in 
follow-up duration, gender (p = 0.114), or disease staging 
(p = 0.174), but we found statistically significant differ-
ences in histology (p = 0.014), age at diagnosis (p = 0.020), 
and recurrence (p = 0.019).
Profile of Economic Resource Consumption and 
Consultations
On average, 36 physical examinations per patient 
were performed (range: 8–90), 84 laboratory tests (range: 
10–173), 2 endoscopies (colonoscopies) (range: 0–4), 
and 15 imaging exams (range: 0–55). These consisted 
mainly of chest X-rays, ultrasonography, and computed 
tomography and, very rarely, magnetic resonance imag-
ing. The average cost of follow-up per patient was EUR 
2,444.85, ranging between EUR 510.62 and 4,918.79. The 
average adjusted annual cost of follow-up per patient was 
EUR 539.09 (Table 2) (Fig. 1). The main contribution to 
this cost was the physical exam (45%), followed by labo-
ratory tests (23%), imaging (26%), and lastly, endosco-
pies (6%). 
A positive association was identified between the cost 
of follow-up and recurrence (p = 0.003). The average ad-
justed annual cost was EUR 796.08 per patient with recur-
rence and EUR 410.61 per patient without recurrence. 
The association between the cost of follow-up and the 
recurrence determined by the area under the ROC curve 
obtained a value of 77%, which reveals a good quality ad-
justment. For a confidence interval of 95%, the lower lim-
it was 69% and the upper limit 99%.
We did not identify any statistically significant differ-
ence by the Mann-Whitney test in the profile of resource 
consumption in patients before and after recurrence; 
however, the size of the sample probably did not have 
enough power to detect statistical significance (p = 0.257). 
In absolute value, for the sample used (n = 10) there was 
a 1.27-fold increase in the cost of follow-up after recur-
10 Mean = 539.10
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Table 2. Descriptive statistics analysis: tests and cost of follow-up per patient
Variable Cases Mean Median SD Min Max
Physical examination, total number 30 35.70 29.50 21.27 8.00 90.00
Laboratory tests, total number 30 84.33 82.00 43.13 10.00 173.00
Endoscopy, total number 30 1.70 2.00 1.29 0.00 4.00
Imaging, total number 30 14.67 11.00 12.45 0.00 55.00
Cost per patient, EUR 30 2,444.85 2,469.39 1,202.86 510.62 4,918.79
Average adjusted annual cost per patient, EUR 30 539.09 435.14 321.05 122.47 1,521.82
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rence (EUR 7,598.46 vs. EUR 9,642.80), attributable to 
imaging exams (p = 0.059) and laboratory tests (p = 
0.650). We also concluded that the duration of follow-up 
had a negative impact (coefficient –0.36) on the adjusted 
annual cost of follow-up per patient (p = 0.049).
When we compared the profile of resource consump-
tion obtained in the study with that obtained by applying 
the ESMO Guidelines, we obtained a cost of EUR 2,775.59 
in the first scenario and EUR 1,433.88 in the second, that 
is, the profile of resource consumption per patient in the 
study was 1.9-fold higher than that obtained when apply-
ing ESMO Guidelines. The main difference can be ex-
plained by the higher number of laboratory tests and im-
aging procedures. The annual adjusted cost of follow-up 
per patient was EUR 578.25 for the study sample and EUR 
298.73 when applying the ESMO Guidelines to the fol-
low-up procedures (Table 3).
Lastly, those patients generated 2,930 follow-up con-
sultations per year, which corresponds to 12% total on-
cology consultations in 2013, 25% of total general surgery 
unit consultations, 35% of total surgery I consultations, 
and 37% of total surgery III consultations at the same in-
stitution.
Discussion
The ongoing discussion in the scientific community 
about the role of primary care in the follow-up of cancer 
patients and the need to define a clinical pathway, clarify 
the follow-up objectives, and identify a discharge cut-off 
from hospital to primary care, as well as a higher focus on 
survivorship are considered essential pillars [25–27]. The 
moment of discharge is considered critical and is aligned 
with cancer survivors’ concerns about the format and 
content of the information shared at the moment of dis-
charge from hospital, among others [28–30]. A choice 
centered on a shared-care model might be considered 
suitable and essentially is the result of a higher proximity 
of care, as identified by several authors [11, 14, 31].
Table 3. Resource consumption per patient in the study when applying ESMO Guidelines at follow-up
Variable (tests/procedures held on average per 
patient with colon cancer with and without 
recurrence)
Study sample ESMO Guidelines at follow-up
57.6 months 36 months 21.6 months 57.6 months
n EUR n EUR n EUR n EUR
Physical examination (total number) 27 837.00 12 372.00 4 111.60 16 483.60
Laboratory tests (total number) 65 424.30 12 86.40 4 25.92 16 112.32
Complete blood count 29 136.30 0 0.00 0 0.00 0 0.00
Liver function tests 24 194.40 0 0.00 0 0.00 0 0.00
Carcinoembryonic antigen test (CEA) 13 93.60 12 86.40 4 25.92 16 112.32
Endoscopies (total number) 2 196.00 1 73.80 0 0.00 1 73.80
Colonoscopy 1 73.80 1 73.80 0 0.00 1 73.80
Colonoscopy with biopsy or polypectomy 1 122.20 0.00 0.00 0 0.00
Imaging (total number) 9 1,318.29 3 477.60 2 286.56 5 764.16
Chest radiography 5 45.00 0.00 0.00 0 0.00
Barium enema radiography 0 0.00 0.00 0.00 0 0.00
Ultrasonography 1 20.12 0.00 0.00 0 0.00
CT of the thorax, abdomen, pelvis 2 441.58 0.00 0.00 0 0.00
CT of the abdomen, pelvis 1 146.09 0.00 0.00 0 0.00
CT of the thorax 1 74.70 0.00 0.00 0 0.00
CT of the column 1 72.40 0.00 0.00 0 0.00
CT of the thorax, abdomen 0 0.00 3 477.60 2 286.56 5 764.16
CT cranioencephalic 5 335.00 0.00 0.00 0 0.00
Magnetic resonance imaging of the abdomen 1 127.90 0.00 0.00 0 0.00
Magnetic resonance imaging of the abdomen, pelvis 0 0.00 0.00 0.00 0 0.00
Magnetic resonance imaging of the column 0 0.00 0.00 0.00 0 0.00
Magnetic resonance imaging cranioencephalic 1 127.90 0.00 0.00 0 0.00
Total 103 2,775.59 28 1,009.80 9 424.08 37 1,433.88
Average adjusted annual cost per patient 578.25 298.73 298.73
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The population characterized in this study is concor-
dant with others in the literature. As observed in other 
studies, patients stay in hospital during follow-up, and 
the majority are followed up by the Oncology Depart-
ment [32]. In this study only 0.4% of cases had follow-up 
secured in primary care, which translates to a significant 
impact in terms of resource allocation and consultation 
management, especially if we consider that 41% of pa-
tients are in follow-up for more than 3 years.
The determination of the profile of resource con-
sumption allowed us to calculate an annual average cost 
of follow-up per patient of EUR 539.09. A Norwich cost-
effectiveness study [9] found an average cost of follow-
up per patient of GBP 351 every 3 months, the equiva-
lent of EUR 484.47 (exchange rate 1.38024 on 14 June 
2015), which means EUR 1,937.88 per year, above the 
number we reached in our study. It is important to high-
light the difference in terms of unit costs between the 
two countries related to the treatment of recurrence and 
travel to hospital, which have not been accounted for in 
our study.
When we compared the profile of resource consump-
tion at follow-up of the patients included in the study 
with the projected resource consumption applying 
ESMO Guidelines, we found that the average cost in the 
study was 1.9 times higher than the theoretical one ap-
plying ESMO Guidelines. This result should be inter-
preted with caution, since the simulated scenario does 
not consider laboratory tests and imaging exams, which 
might have been needed during a suspicion of recur-
rence or other need, and only included the routine tests 
and/or exams performed. The consultation burden with 
these patients is considerable; putting in perspective 
around 2,930 follow-up appointments per year com-
pared with 1,585 first consultations registered by the 
Oncology Department in 2013 [33]. The hospital pro-
duction in continental Portugal in 2014 was 9,308 pa-
tients with colon cancer, rectal cancer, rectum-sigmoid 
junction cancer, and anal cancer. Of the total number of 
patients submitted to oncologic surgery, 16.0% waited 
longer than the maximum recommended time [2]. Bear-
ing in mind that in our study oncology and surgery were 
the specialties that played the largest role in the follow-
up of colorectal cancer patients, we can assume a sig-
nificant impact on hospital care management with those 
patients as the number of new cancer patients and first-
time appointments increases.
This study has several limitations. The fact that the 
analysis was based on a single, highly differentiated uni-
versity hospital as the source of patients might have bi-
ased some of the results, and the study population may 
not have been representative of the national reality; 
however, we chose it because it is a centralized general 
hospital with an important oncology component. Sec-
ondly, a sample power calculation was not performed. 
Also, it is important to mention that the data access goes 
back to the Medicine Academic Centre of Lisbon data-
base, which includes colorectal patients registered from 
2008 to 2013. The quality of data depends on the quality 
and reliability of the information registered by physi-
cians.
Thirdly, the calculation of the profile of resource con-
sumption took into consideration only patients at stage 
II of disease, since it was the most common stage in the 
study sample (36.4%) and associated with a 5-year sur-
vival rate of 82.5%, which is associated with an increase 
in the number of colorectal cancer survivors [34]. The 
sample used represents 6% of the total study sample 
(n = 506) but 16% of total stage II patients (n = 186), 
which was the sample analyzed. As a descriptive analysis 
of only resource consumption, we divided the sample 
into two groups, 20 cases without recurrence (67%) and 
10 cases with recurrence (33%). At stage II, local recur-
rence after surgery with curative intent ranged between 
3% and 30%, which serves as a reference for the split 
used [35]. 
The data collection was retrospective, which might 
have introduced bias. To minimize limitations due to 
the lack of registry by physicians, electronic patient files 
were used, which nevertheless does not exclude the cas-
es where patients were doing some procedures in a pri-
vate health-care setting.
For the resource consumption profile, we used as a 
reference the values at Portaria No. 20/2004 as an ac-
ceptable costs approach and not the values for hospital 
financing from Contrato Programa. As an example, we 
used EUR 31 (Portaria No. 20/2014) per hospital ap-
pointment and not EUR 70.12 for subsequent appoint-
ments at Contrato Programa, which also includes ex-
ams.
Fourthly, the fact that experts have been chosen based 
on their knowledge and higher engagement with this 
topic cannot exclude the possibility of different conclu-
sions being obtained in another context, although the 
conclusions in our study are completely aligned with the 
international literature. In agreement with other inves-
tigators [10], we conclude that there exist three key ele-
ments: knowledge transfer, communication channels, 
and active patient involvement.
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Conclusion
Colorectal cancer is the third most prevalent cancer. 
Two-thirds of currently diagnosed cancer patients will 
survive for at least 5 years, and among those, two-thirds 
are older than 65 years; as such, the probability of a fam-
ily physician having a cancer survivor older than 65 years 
is 1 in 6 [36], implying serious challenges to health-care 
professionals and managers, with a varied range of needs 
to be answered – physical, psychosocial, and economic. 
The follow-up of cancer patients is centered on recur-
rence detection, late side effect monitoring, identification 
of new primary cancers, and psychological support. Fol-
low-up in hospital is under discussion, and a new variant 
based on the role of the primary care setting is being in-
troduced [37]. The available evidence supports the hy-
pothesis that follow-up by family physicians is a valid op-
tion and that they are willing to assume such a role. The 
existence of channels between the family physician and 
the hospital team beyond the patient’s clinical informa-
tion is fundamental, as is a protocol for follow-up accept-
ed by both parties where one is available.
As verified in the case study, the impact of in-hospital 
colorectal patient follow-up on economics and the num-
ber of appointments is meaningful. Follow-up in the pri-
mary care setting can emerge as an equally effective but 
less costly modality. To generate a virtuous cycle, regula-
tors and payers have an important role to play, ensuring 
proper primary care financing and an organizational 
model with the creation of specific indicators for shared-
care follow-up in conjunction with health-care profes-
sionals, which compensate good performance and repre-
sent a health gain to the cancer survivors, translating to 
more and better care while respecting cost-effectiveness, 
quality of care, and the results obtained. 
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